Table 2 Medical and health variables of the study

Drug

301

100%

264

88%

37

12%

 temozolamide

42

14%

41

14%

1

0%

 bevacizumab

39

13%

33

11%

6

2%

 rituximab

26

9%

24

8%

2

1%

 pazopanib

25

8%

18

6%

7

2%

 pembrolizumab

15

5%

15

5%

0

0%

 ibrutinib

15

5%

14

5%

1

0%

 bortezomib

10

3%

9

3%

1

0%

 Others

129

43%

110

37%

19

6%

ICD-10^a

301

100%

264

88%

37

12%

 C-71malignant neoplasm of brain

40

13.3%

39

13%

1

0.3%

 C-90 multiple myeloma and malignant plasma cell neoplasms

38

12.7%

33

11%

5

1.7%

 C-53 malignant neoplasm of cervix uterin

28

9.3%

24

8%

4

1.3%

 C-64 malignant neoplasm of kidney, except renal pelvis

26

9%

20

7%

6

2.0%

 C-43 malignant melanoma of skin

15

5%

15

5%

0

0.0%

 C-91 lymphoid leukemia

15

5%

12

4%

3

1.0%

 C-18 malignant neoplasm of colon

13

4.3%

12

4%

1

0.3%

 C-50 malignant neoplasm of breast

12

3.7%

10

3%

2

0.7%

 C-81 Hodgkin lymphoma

8

2.7%

3

1%

5

1.7%

 C-82 Follicular lymphoma

5

2%

5

2%

0

0.0%

 Others

101

33.3%

91

30%

10

3.3%

Origin of the report

301

100%

264

88%

37

12%

 Public

271

90%

237

78%

34

11%

 Private

30

10%

27

9%

3

1%